Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
Chad C. Bjorklund(Bristol-Myers Squibb (United States)), Anjan Thakurta(University of Oxford)
Cited by 216
Related Papers
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
|Blood|2018|492
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
|Leukemia|2018|452
Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide
|Journal of Biological Chemistry|2010|129